{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae EA IgG",
        "LIAISON\u00ae Control EA IgG",
        "LIAISON\u00ae EA IgG Assay",
        "LIAISON\u00ae EA IgG Controls"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K060204",
    "Predicate Device Reference 510(k) Number(s)": [
        "K992191"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "LSE"
    ],
    "Summary Letter Date": "October 6, 2006",
    "Summary Letter Received Date": "October 13, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3235"
    ],
    "Regulation Name(s)": [
        "Epstein-Barr virus Serological Reagents"
    ],
    "Analyte Class(es)": [
        "immunology",
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Epstein-Barr virus early antigen-diffuse [EA(D)] IgG"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Indirect immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae EA IgG immunoassay for qualitative detection of IgG antibodies to Epstein-Barr virus early antigen-diffuse using CLIA technology.",
    "Indications for Use Summary": "Qualitative determination of IgG antibodies to Epstein-Barr virus early antigen-diffuse [EA(D)] in human serum, as an aid in diagnosing Epstein-Barr viral syndrome in patients with signs and symptoms of EBV infection such as infectious mononucleosis.",
    "fda_folder": "Microbiology"
}